Latest Blueprint Medicines News & Updates

See the latest news and media coverage for Blueprint Medicines. We track all announcements, press releases, and industry mentions in real time, all in one place.

Blueprint Medicines

Global biopharmaceutical company

blueprintmedicines.com

Headquarters: Cambridge, United States
Founded year: 2011
Company type: Public company
Number of employees: 700–1,000

Last updated Today

Latest news about Blueprint Medicines

In short: Blueprint Medicines agreed to be acquired by Sanofi for $9.5 billion and regained global rights to Gavreto after Roche terminated their partnership.

Company announcements

February 28 Blueprint Medicines

Blueprint Medicines announces four-year PIONEER data for AYVAKIT

Data show sustained symptom control, quality of life improvement, and long-term safety in indolent systemic mastocytosis patients. Presented at 2026 AAAAI Annual Meeting.

5 December 2025 Blueprint Medicines

Blueprint Medicines highlights AYVAKIT long-term benefits at ASH

Data from PIONEER and PATHFINDER trials show sustained symptom control, quality-of-life improvements, prolonged survival, and bone health benefits in ISM and advanced SM.

12 June 2025 Blueprint Medicines

Blueprint Medicines announces AYVAKIT data at EHA and EAACI

Data from PIONEER, PATHFINDER, and EXPLORER trials reinforce sustained efficacy and safety in systemic mastocytosis treatment. Presentations include oral and flash talks.

2 June 2025 Blueprint Medicines

Sanofi agrees to acquire Blueprint Medicines

The deal values Blueprint at $9.1 billion upfront, plus up to $0.6 billion in CVRs for BLU-808 milestones. It adds Ayvakit for systemic mastocytosis and immunology pipeline to Sanofi's portfolio.

Media coverage

June 3 HCPLive

Avapritinib Demonstrates Durable Improvements in Indolent Systemic Mastocytosis Symptoms, QoL | HCPLive

These compelling results have ... and treatment durations trending toward multiple years,” Becker Hewes, MD, Chief Medical Officer at Blueprint Medicines, said in an earlier...

March 7 Pharmaceutical Executive

Roche Terminates Cancer Treatment Pact With Blueprint Medicines | PharmExec

Blueprint Medicines Corporation will regain global commercialization and development rights to Gavreto (pralsetinib).

March 3 European Pharmaceutical Review

Blueprint’s rare disease drug Ayvakit shows long-term benefit

New four-year clinical data from Blueprint Medicines, a Sanofi company, show that Ayvakit (avapritinib) enabled sustained symptom control in patients with the rare disease indolent...

February 28 Morningstar

Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis

CAMBRIDGE, Mass., Feb. 28, 2026 /PRNewswire/ -- Blueprint Medicines, a Sanofi company, today announced AYVAKIT® (avapritinib) data showing clinically meaningful outcomes and a well-tolerated long-term...

Never miss news about Blueprint Medicines

Track Blueprint Medicines and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.